ArticleThe journal of prevention of Alzheimer's disease2021
Aducanumab: Appropriate Use Recommendations.
Article in The journal of prevention of Alzheimer's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
184 citing papers in PubMed, 7 syntheses or guidelines pooled it, 274 citations in OpenAlex.
- Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Pooled it
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application.Journal of medical Internet research · 2025Pooled it
- Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis.Journal of neurology · 2025Pooled it
- The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Efficacy and Safety of Probiotics for the Treatment of Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease: A Systematic Review and Meta-Analysis.Frontiers in aging neuroscience · 2022Pooled it
- Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial.Nature communications · 2025Trial
- Eligibility for donanemab trial in a population-based study of cognitive aging.The journal of prevention of Alzheimer's disease · 2025Trial
- Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease.Nature aging · 2021Trial
- Cognitive heterogeneity in mild cognitive impairment due to Alzheimer's disease pathology.Neural regeneration research · 2026Article
- Morbidity and medication use preceding a diagnosis of late-onset Alzheimer's disease: a Danish nationwide study.Journal of neurology · 2026Article
- Exploring the Gut-Brain Connection: Are Probiotics the Next Frontier in Alzheimer's Disease Treatment?Probiotics and antimicrobial proteins · 2026Review
- The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease staging.Alzheimer's research & therapy · 2026Article
- Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Feasibility of identifying factors related to Alzheimer's disease and related dementia in real-world data.JAMIA open · 2026Review
- Baseline plasma p-tau217/Aβ42 as a sensitive marker for the severity of Alzheimer's disease continuum.Journal of translational medicine · 2026Article
- Silent Intruders: The Gut Virome in Brain Aging and Cognitive Decline.Pathogens (Basel, Switzerland) · 2026Review
- Ultra-fast MRI for brain-age prediction in a real-world cognitive disorders clinic.Frontiers in aging neuroscience · 2026Article
- Revolutionizing Therapeutic Approaches Against Pathophysiology of Alzheimer's Disease: A Therapeutic Review.Current aging science · 2026Review
124 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
Abstract
Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new therapy. An Expert Panel was assembled to construct Appropriate Use Recommendations based on the participant populations, conduct of the pivotal trials of aducanumab, updated Prescribing Information, and expert consensus. Aducanumab is an amyloid-targeting monoclonal antibody delivered by monthly intravenous infusions. The pivotal trials included patients with early AD (mild cognitive impairment due to AD and mild AD dementia) who had confirmed brain amyloid using amyloid positron tomography. The Expert Panel recommends that use of aducanumab be restricted to this population in which efficacy and safety have been studied. Aducanumab is titrated to a dose of 10 mg/kg over a 6-month period. The Expert Panel recommends that the aducanumab be titrated to the highest dose to maximize the opportunity for efficacy. Aducanumab can substantially increase the incidence of amyloid-related imaging abnormalities (ARIA) with brain effusion or hemorrhage. Dose interruption or treatment discontinuation is recommended for symptomatic ARIA and for moderate-severe ARIA. The Expert Panel recommends MRIs prior to initiating therapy, during the titration of the drug, and at any time the patient has symptoms suggestive of ARIA. Recommendations are made for measures less cumbersome than those used in trials for the assessment of effectiveness in the practice setting. The Expert Panel emphasized the critical importance of engaging in a process of patient-centered informed decision-making that includes comprehensive discussions and clear communication with the patient and care partner regarding the requirements for therapy, the expected outcome of therapy, potential risks and side effects, and the required safety monitoring, as well as uncertainties regarding individual responses and benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.